Board of Directors
This section provides the financial market, owners and other interested parties with correct, relevant and timely information about our business and our performance. Investor information is released in Swedish for regulatory reasons and translated into English on a report-to-report basis. Please contact Redsense for additional information.
Patrik Byhmer
Chair of the Board
Elected Chairman: 2022
Previous positions: Patrik Byhmer is the founder of Redsense Medical and has since its inception served as CEO of Redsense Medical AB and Redsense Medical Inc. He has extensive experience leading global businesses, managing staff, distribution networks, agents and production outside Europe. Has worked in marketing at Procter & Gamble, has been BU director for medical technology companies with global distribution (Etac AB), has set up new technology business operations in mobile technology (global V.P. Sales & Marketing gigaAnt, Perlos (present Lite-On), AnteNova).
Shareholding: Owns privately and via companies 1 720 414 shares
Susanne Olauson
Member of the Board
Elected: 2013
Previous positions: Susanne Olauson is currently the CEO of Odinwell AB. She has twenty years of sales experience in the pharmaceutical industry, the medical technology industry and life science. Has held positions as VP Commercial Operations, European Congress Manager, Director Sales & Marketing development, product specialist and product manager in medical technology and pharma.
Malin Almgren
Member of the Board
Elected: 2023
Malin Almgren has a master’s degree in Biochemistry and a PhD in medical research and has over 20 years of experience in the research field. She has worked for over two decades at esteemed institutions such as Karolinska Institutet and UCSD, gaining expertise in various fields like genetics/epigenetics, immunology, neuroscience, and oncology. Her experience also includes working on clinical trials and collaborations with the industry. Aside from her scientific expertise, Malin has also developed a second career within finance. She has worked at a Swedish asset management firm, Tundra Fonder, with focus on sustainable investments. Additionally, she has worked as a financial advisor for M&A transactions in the healthcare sector at Experia Corporate Finance Advisors.
Currently, Malin is CEO of Schain Research AB, where she uses her knowledge of both science and economics to drive the company’s success. She is also a board member at Experia Nordic Oy.
Lena Oswald
Member of the Board
Elected: 2023
Lena Oswald has a strategic profile with a focus on building and developing companies commercially and internationally. Thirty years of experience as advisor at a high level in all types of companies. Lena has knowledge, experience and ability to position companies, brands, develop assortments and sales channels (subsidiaries, distributors) and markets globally. She is specialized in the connection between business strategy, organization and people. Lena combines a holistic view, from the outside in perspective, with implementation and action.
Executive Chairman of Bolon from 2017, a family-owned Swedish floor design company with international operations. Board member of Form Us With Love from 2022, an industrial design company with venture/incubator operations. Chairman of InterPares, a management consulting company that she has been active in since 2014.
Eva Walde
Member of the Board
Elected: 2023
Eva Walde holds a Master of Science in Business and Economics from the School of Economics in Gothenburg. She has over 30 years of experience in senior positions in pharmaceuticals, medical devices, diagnostics and biotechnology industries, mainly in marketing and sales. Most recently, Eva was VP Global Marketing at Olink Proteomics AB.
Previously, she has held roles as VP Commercial Operations, International Region at Phadia/ThermoFisher Scientific and Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB. Eva is a board member of Sedana Medical AB since 2018, Senzime AB since 2020 and Scale Up Life Science AB since 2023.